Drug Trial Radar · NCT01690975
Benzonatate Dose Tolerance Study
Last checked: Nov 20, 2026Latest source record: Sep 24, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
Jul 2012
Primary completion
Aug 2012
Study completion Aug 2012
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Sep 24, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, randomized, third party blind, placebo controlled, dose escalation study of benzonatate following single dose administration. The primary oobjective is to assess the safety and tolerability of increasing oral doses of benzonatate following single dose administration in healthy male and female subjects.
Conditions
- Cough
Interventions
PlaceboDrug
Placebo - single dose at start of each treatment period
Benzonatate - 400 mgDrug
Benzonatate - 400 mg single dose
Benzonatate - 600 mgDrug
Benzonatate - 600 mg single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax)Time frame: 0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose
- Time to Reach Maximum Observed Plasma Concentration (Tmax)Time frame: 0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose
- Plasma Decay Half-Life (t1/2)Time frame: 0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose
- Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)Time frame: 0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose
- Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)Time frame: 0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pfizer Investigational Site
New Haven, Connecticut
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.